Technology, Healthcare, Consumer Staples Dec 03, 2021 03:59 PM (GMT+8)
Financial Associated Press, Dec. 3 (Reuters) - Alex announced that the company's product vometinib mesylate passed the medical insurance negotiation and was included in the national catalogue of drugs for basic medical insurance, industrial injury insurance and maternity insurance (2021) for the first time. Vometinib mesylate tablet is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It is a class 1 new drug independently developed by the company. It is a small molecule targeted drug for the treatment of advanced non-small cell lung cancer.
This text is a result of machine translation.